SUNDAY,SEPTEMBER 2 ND 2012 122. Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management P1291 Clinical and socioeconomic profile of asthmatic patients treated in a terciary/university hospital in Brazil Rogerio Rufino 1 , Eduardo Costa 2 , Mauricio Bregman 1 , Claudia Costa 1 , Denizar Vianna 2 . 1 Pulmonology Unit, State University of Rio de Janeiro, Rio de Janeiro, Brazil; 2 Internal Medicine Department, State University of Rio de Janeiro, Rio de Janeiro, Brazil Introduction: Bronchial asthma has a high prevalence, morbidity, and impact on quality of life worldwide. Its associated costs are still unknown in Brazil. Objective: The aim is to describe clinical and socio-economic characteristics of asthmatic patients in treatment in specialized units at a public university hospital in Brazil as part of a cohort study on costs of asthma treatment. Methods: It’s a cohort study of patients above 6 years of age with persistent asthma, which were interviewed 2 times with 6 months interval using a standard- ized instrument to collect data. Results: 117 asthmatics were enrolled (72.6% of female gender). Average age was 44.3 years (SD=20.7) and average mensal family income was US$ 766.50 (SD=616.54). The average duration of asthma was 23.2 years (SD=17.5) and 103 patients (88%) has had associated rhinitis. 59 patients (50.4%) had mild, 42 (36%) had moderate and 16 (13.6%) had severe asthma and 43.6% of all patients had their asthma well controlled, 37.6% were partially controlled and 18.8% were not controlled. All patients were using daily medication to control asthma. Only 30.7% had money expenditures for allergen avoidance measures. Conclusions: We discovered a low income profile among patients. Due to the low level of organization of Brazilian Health System a great proportion of mild asthmatics are treating their disease in a tertiary hospital. Although all patients are using some control medication, almost 1/5 of them were not controlled. Rhinitis is a frequent co-morbidity probably influencing the severity and control of dis- ease. A low proportion of patients are using immunotherapy and making allergen avoidance measures. P1292 A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD Yumi Asukai 1 , Jaithri Ananthapavan 1 , Bill Malcolm 2 , Amr Radwan 3 , Ian Keyzor 4 . 1 Health Economics and Outcomes Research, IMS Health, London, United Kingdom; 2 Scientific Operations, Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom; 3 Clinical Development & Medical Affairs, Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom; 4 Health Economics and Outcomes Research, Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom Introduction: COPD is a chronic incurable disease; however, there are effective treatments available. In the UK, long-acting bronchodilators are first-line treat- ments for COPD patients requiring maintenance therapy, and there are several options available. Aim: To establish from the UK NHS perspective, the cost-effectiveness (CE) profile of indacaterol, the first once-daily LABA, compared to tiotropium and salmeterol, in patients with moderate to severe COPD. Methods: A Markov model was developed with four health states describing the GOLD severity stages. From each of the states, patients could experience a severe or non severe exacerbation, move to a different COPD state, remain in the current state or die. Transition probabilities were based on data from the indacaterol clini- cal trials. Cost and resource use data was taken from UK based sources, published literature and expert opinion. Sensitivity analyses (SA) were also conducted. 238s Thematic Poster Session Halle A-42 - 12:50 - 14:40 Abstract printing supported by . Visit Chiesi at Stand B2.10